BOSTON and SALT LAKE CITY and FULTON, Md., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Clairity, Myriad Genetics, Inc. (NASDAQ: MYGN), and MagView, today announced a joint collaboration in an effort to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens.

The agreement brings together three leaders in breast cancer:

• Clairity – developer of Clairity Breast, the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram
• Myriad Genetics – a leader in molecular diagnostic testing and precision medicine, offering the MyRisk^® Hereditary Cancer Test with RiskScore^®, which combines genetics, clinical factors (Tyrer-Cuzick), and polygenic risk
• MagView – a leader in comprehensive software solutions for breast imaging centers

For the first time, clinicians and patients will have access to an integrated view of genotype (Myriad’s MyRisk with RiskScore test) and phenotype (Clairity Breast) through MagView’s Luminary Risk platform, which supports breast cancer risk assessment programs across the United States.

“By integrating directly with MagView alongside Myriad, we are giving clinicians a more complete and actionable view of risk than can be achieved using age and family history alone,” said Jeff Luber, CEO, Clairity, “Using AI-powered risk assessment, Clairity Breast identifies women at the highest risk from a routine mammogram.”

“Effective screening of individuals with elevated risk of cancer is an important part of the cancer care continuum,” said Sam Raha, President and CEO, Myriad Genetics. “By pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, we aim to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer.”

“Our platform streamlines how risk information is captured, interpreted, and acted on,” said Bryan Chapin, President and CEO, MagView. “Integrating Clairity and MyRisk into one platform gives providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency.”

About Clairity

Clairity is an AI-powered precision health company transforming medical imaging into a predictive tool for early risk assessment. Its flagship product, Clairity Breast, is the first and only FDA-authorized offering to estimate a woman’s five-year breast cancer risk directly from a routine mammogram. By shifting care from detection to prevention, Clairity empowers health systems, radiologists, and women to act earlier, save lives, and lower the overall cost of cancer care. To learn more about indications for use, visit: https://clairity.com/clairity-breast/.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad Genetics develops and offers molecular tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where molecular insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.

About MagView

MagView is the leader in breast imaging workflow solutions for mammography reporting, tracking, workflow, compliance, and high-risk screening. Headquartered in Fulton, Maryland, MagView’s Luminary Risk software embeds into EHRs to enable breast centers to adopt a more personalized approach to breast cancer screening, focusing on patient experience and staff efficiency. MagView is utilized by more than 2,500 facilities across the U.S., including many of the nation’s top cancer centers. For more information about MagView, please visit www.magview.com.

Myriad Genetics Safe Harbor Statement

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to how the joint collaboration aims to identify more women at high risk for breast cancer, with the goal of addressing a critical gap in breast cancer risk assessment without creating additional administrative burdens; expectations that integrating Clarity into MagView alongside Myriad gives clinicians a more complete and actionable view of risk than can be achieved using age and family history alone; by pairing the MyRisk Hereditary Cancer Test with Clairity’s AI-powered risk assessment within MagView’s workflow, Myriad aims to empower clinicians with actionable results, helping to enable earlier, more personalized interventions in the fight against breast cancer; and statements regarding the potential for the integration of Clairity Breast and MyRisk into one platform to give providers a powerful, unified tool to support proactive breast health management, while improving workflow efficiency. These “forward-looking statements” are management’s expectations of future events as of the date hereof and are subject to known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. Such factors include those risks described in the company’s filings with the U.S. Securities and Exchange Commission, including the company’s Annual Report on Form 10-K filed on February 28, 2025, as well as any updates to those risk factors filed from time to time in the company’s Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. Myriad is not under any obligation, and it expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law.

Investor Contact
Matt Scalo
(801) 584-3532
This email address is being protected from spambots. You need JavaScript enabled to view it.

Media Contact
Kate Schraml
(224) 875-4493
This email address is being protected from spambots. You need JavaScript enabled to view it.